Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 743,266	$ 14	$ 1,253,971	$ 893	$ (511,612)
Beginning Balance, Shares at Dec. 31, 2020		137,646,896
Issuance of common stock upon exercise of common stock warrants, Shares		54,162
Issuance of common stock for cash upon exercise of stock options	14,442		14,442
Issuance of common stock for cash upon exercise of stock options, Shares		2,183,640
Common stock option and restricted stock unit share-based compensation	8,484		8,484
Capital contributions for Digital Biotechnologies, Inc.	429		300			$ 129
Other comprehensive loss	(262)			(262)
Net loss	(40,642)				(40,642)
Ending Balance at Mar. 31, 2021	725,717	$ 14	1,277,197	631	(552,254)	129
Ending Balance, Shares at Mar. 31, 2021		139,884,698
Beginning Balance at Dec. 31, 2021	604,102	$ 14	1,324,006	(1,137)	(718,891)	110
Beginning Balance, Shares at Dec. 31, 2021		141,393,865
Issuance of common stock for cash upon exercise of stock options	$ 2,734		2,734
Issuance of common stock for cash upon exercise of stock options, Shares	648,208	648,208
Vesting of restricted stock units		141,185
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	$ 12,861		12,861
Other comprehensive loss	(3,646)			(3,646)
Net loss	(62,796)				(62,736)	(60)
Ending Balance at Mar. 31, 2022	$ 553,255	$ 14	$ 1,339,601	$ (4,783)	$ (781,627)	$ 50
Ending Balance, Shares at Mar. 31, 2022		142,183,258